Neurogene Inc.

NGNE

NASDAQ

Healthcare

Biotechnology

New York City, NY, US107 employeesneurogene.com

$21.45

-0.21(-0.97%)

Mkt Cap $334M

$7.34

$34.37

52-Week Range

At a Glance

AI-generated

Revenue breakdown: Reportable Segment (100%).

8-K

Neurogene Inc. announced full year 2025 financial results, reporting net loss of $90.4 million, R&D expenses of $75.0 million, G&A expenses of $28.3 million, and cash, cash equivalents and short-term investments of $269.0 million as of December 31, 2025, providing runway through first quarter of 2028. Highlights include 100% enrollment in Embolden registrational trial for NGN-401, >50% participants dosed, and FDA Breakthrough Therapy designation.

$334M

Market Cap

—

Revenue

-$62M

Net Income

Employees107

Fundamentals

How The Business Makes Money

Revenue by Segment

Reportable Segment100%($925.0K)

Activity

What Changed Recently

Financial Results

Mar 23, 2026

and Exhibit s 99.1 and 99.2 attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of

Regulation FD

Feb 25, 2026

and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as a

Regulation FD

Jan 11, 2026

and Exhibits 99.1 amd 99.2 attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of

Peer Companies

Company	Price	Change	Market Cap	P/E
ALMSAlumis Inc. Common Stock	$23.42	+3.04%	$2.9B	-10.1
OCGNOcugen, Inc.	$1.78	-0.28%	$585M	-9.7
SLDBSolid Biosciences Inc.	$7.49	+1.42%	$583M	-3.9
ADCTADC Therapeutics S.A.	$3.80	+0.03%	$483M	-4.3
FULCFulcrum Therapeutics, Inc...	$8.06	+7.75%	$436M	-5.8
LCTXLineage Cell Therapeutics...	$1.56	-1.57%	$390M	—
AUTLAutolus Therapeutics plc	$1.42	+2.90%	$378M	-1.7
PRTCPureTech Health plc	$15.51	+3.40%	$377M	7.3

Analyst View

Company Profile

CIK0001404644

ISINUS64135M1053

CUSIP64135M105

Phone(877) 237-5020

Address535 W 24th Street, New York City, NY, 10011, US

SEC EDGAR